Results 241 to 250 of about 32,319 (328)

Protectin D1 and maresin 1 attenuate airway hyperreactivity induced by IL‐13 in human isolated small bronchi

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Interleukin (IL)‐13 is implicated in airway hyperreactivity (AHR), a key feature of asthma. We explored the potential anti‐AHR activity of selected specialised pro‐resolving mediators (SPMs) in IL‐13‐induced AHR models, using human bronchial smooth muscle cells (BSMCs) and human isolated bronchi.
Willem Abma   +9 more
wiley   +1 more source

Obesity: Next game changer of allergic airway diseases? [PDF]

open access: yesClin Transl Med
Li W, Marx N, Yang Q, Fang D, Zhang Y.
europepmc   +1 more source

Homo sapiens, industrialisation and the environmental mismatch hypothesis

open access: yesBiological Reviews, EarlyView.
ABSTRACT For the vast majority of the evolutionary history of Homo sapiens, a range of natural environments defined the parameters within which selection shaped human biology. Although human‐induced alterations to the terrestrial biosphere have been evident for over 10,000 years, the pace and scale of change has accelerated dramatically since the onset
Daniel P. Longman, Colin N. Shaw
wiley   +1 more source

Immunological Status of Saliva in Children with Asthma by Disease Severity. [PDF]

open access: yesInt J Clin Pediatr Dent
Leshchuk S, Hakami Z, Vishwanathaiah S.
europepmc   +1 more source

Nutraceuticals Against Oxidative Stress in Allergic Diseases. [PDF]

open access: yesBiomolecules
Di Salvo M   +4 more
europepmc   +1 more source

Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK‐air Study

open access: yesClinical &Experimental Allergy, Volume 55, Issue 3, Page 226-238, March 2025.
In a study assessing mobile health data, (i) adherence to rhinitis medication was highest for oral antihistamines and lowest for azelastine‐fluticasone, (ii) in weeks of partial adherence, azelastine‐fluticasone was associated with lower levels of reported rhinitis symptoms than other medication classes.
Bernardo Sousa‐Pinto   +121 more
wiley   +1 more source

Early and Sustained Asthma Control and Remission in Real‐World Patients With Severe Eosinophilic Asthma Treated With Benralizumab: XALOC‐2

open access: yesClinical &Experimental Allergy, EarlyView.
Real‐world patients with severe eosinophilic asthma treated with benralizumab showed early and sustained improvements in symptoms. Clinically meaningful improvements began as early as one week after benralizumab initiation, regardless of previous biologic use, and further improved over the following year.
Erika Penz   +12 more
wiley   +1 more source

Molecular profiling of exhaled breath condensate in respiratory diseases. [PDF]

open access: yesAnn Med
Malerba M   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy